viewExpress, Inc.

Express Inc. shares drop nearly 25% following negative Q2 results

Poor sales for the retail apparel company lead shares to lowest level since November

Clothing retailer Express Inc. saw its shares fall on poor sales results
Clothing retailer Express Inc. saw its shares fall on poor sales results

Express Inc. (NYSE:EXPR) shares fell sharply on Wednesday after the specialty retail apparel company released showing second quarter results lower than analysts were expecting and the firm's CEO offered a candid appraisal.

The company’s net sales decreased 6% to $504.8mln from $535.6mln in the same period in 2015. E-commerce sales dropped 7% to $70.1 mln.

“I am disappointed with our second quarter performance as sales and earnings were below our guidance, reflecting challenging store traffic,” said CEO David Kornberg. “This was compounded by a lack of clarity across the assortment.”

Kornberg said that Express’ leadership team believed they had identified ways to reposition the company for success.

“Our fall assortment is more cohesive across our wearing occasions, clearly identifying the important trends, and we are aggressively pursuing several marketing initiatives focused on driving new customer acquisition and retention,” Kornberg said. The company’s overall inventory position heading into the fall season was also favorable, he noted.

Express shares were down 24.83% to $12.05.

Quick facts: Express, Inc.

Price: 4.92 USD

Market: NYSE
Market Cap: $313.78 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



CytoDyn reveals more promising results from its clinical trials in breast cancer

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the late-stage biotechnology company has revealed additional “promising results” from its clinical trials evaluating its lead drug leronlimab for the treatment of metastatic triple-negative breast cancer and metastatic breast...

1 hour, 47 minutes ago

2 min read